Table 2. Maximal IOP values in patients carrying various alleles of N363S, Bcl I, and ER22/23EK polymorphisms.

SNP	Genotype	Maximal IOP during steroid therapy (mmHg, mean±SD)
		Analysis A1	Analysis A2	Analysis B
N363S	WT:AA	18.2±4.3 (n=124)	24.4±8.1 (n=37)	23.4±7.9 (n=70)*
	P:AG	16.0±1.2 (n=8)	27.7±6.2 (n=5)	31.0±7.8 (n=6)*
Bcl I	WT:GG	18.4±4.3 (n=64)	26.7±8.4 (n=23)	25.0±8.9 (n=26)
	P:GC,CC	17.7±4.1 (n=68)	22.5±6.8 (n=19)	23.4±7.3 (n=40)
ER22/23EK	WT:GG	18.0±4.3 (n=131)	24.5±8.0 (n=39)	24.0±8.2 (n=72)
	P:GC,CC	19.0 (n=1)	27.8±6.0 (n=3)	26.3±4.9 (n=4)

Patients carrying the G allele of the N363S polymorphism had significantly higher maximal IOP during the prednisolone acetate treatment (marked with asterisks, p=0.03). Other factors, like frequency of Bcl I and ER22/23EK polymorphisms, photoablation depth, and initial IOP, were statistically significant neither in analysis groups A1 and A2 nor in analysis group B. Abbreviations: SNP: Single nucleotide polymorphism, WT: wild type, P: polymorphic genotype, n: number of eyes studied.